Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Oesophageal atresia with or without tracheo-oesophageal fistula

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15651
R64620
Blotière (Indications other than epilepsy), 2019 Atresia of esophagus 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 4.90 [0.10;27.40] 1/980   392/1,875,733 393 980
ref
S15601
R64296
Tinker (Mixed indications), 2019 Esophageal atresia/stenosis 1st trimester case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 0.73 [0.10;5.43] C 1/22   752/12,264 753 22
ref
S17865
R75464
Eros (Indications NOS), 2002 Esophageal atresia/stenosis during pregnancy (anytime or not specified) excluded case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched no data
excluded (exposition period)
0/-   -/- - -
ref
Total 2 studies 1.45 [0.24;8.75] 1,146 1,002
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Indications other than epilepsy), 2019Blotière, 2019 1 4.90[0.10; 27.40]39398036%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker (Mixed indications), 2019Tinker, 2019 2 0.73[0.10; 5.43]7532264%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 15% 1.45[0.24; 8.75]1,1461,0020.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 4.90[0.30; 81.11]393980 -NABlotière (Indications other than epilepsy), 2019 1 case control studiescase control studies 0.73[0.10; 5.43]75322 -NATinker (Mixed indications), 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.45[0.24; 8.75]1,1461,00215%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 Tags Adjustment   - No  - No 1.45[0.24; 8.75]1,1461,00215%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 4.90[0.30; 81.11]393980 -NABlotière (Indications other than epilepsy), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 0.73[0.10; 5.43]75322 -NATinker (Mixed indications), 2019 1 All studiesAll studies 1.45[0.24; 8.75]1,1461,00215%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.45[0.24; 8.75]1,1461,00215%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.510.01.0